Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Taysha Gene Therapies, Inc. focuses on Biotechnology services and products. Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic. The company carries a $1.71B market cap, placing it firmly in the small-cap category. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Market Cap
$1.71B
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
-13.70
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.43
ROE
-97.3%
ROA
-37.8%
Cash
$276.6M
Total Debt
$68.6M
Free CF
-$73.4M
52W Change
131.9%
Annual Financials
Cash vs Debt
Taysha Gene Therapies, Inc. holds $276.6M in cash against $68.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$73.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -97.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.5M (2022) to $9.8M (2025), reflecting a 291% increase over the period.
With cash comfortably exceeding debt, TSHA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Taysha Gene Therapies, Inc.'s trajectory.